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Abstract 
Background: Monoclonal antibodies (mAb) that block programmed death (PD)-1 signaling pathway hold great 
potential as a novel cancer immunotherapy. Recent evidence suggests that combining with conventional, targeted 
or other immunotherapies, these mAb can induce synergistic antitumor responses. In this study, we investigated 
whether Trabectedin (ET-743), a novel anticancer agent currently used for treating relapsed ovarian cancer, can syner-
gize with anti (α)-PD-1 mAb to increase antitumor activity in the murine ID8 ovarian cancer model.
Methods: Mice with established peritoneal ID8 tumor were treated with either single or combined Trabectedin 
and α-PD-1 mAb, their overall survival was recorded; tumor-associated immune cells and immune gene expression 
in tumors from treated mice were analyzed by flow cytometry and quantitative RT-PCR, respectively, and antigen-
specific immunity of effector CD8+ T cells was evaluated by ELISA and cytotoxicity assay. In addition, the effect of 
Trabectedin on tumoral PD-L1 expression was analyzed by both flow cytometry and immunofluorescence staining.
Results: Though single treatment showed a modest antitumor effect in mice bearing 10-day-established ID8 tumor, 
combined Trabectedin and α-PD-1 mAb treatment induced a strong antitumor immune response, leading to a 
significant tumor regression with half of mice tumor-free 90 days after tumor inoculation. Mechanistic investigation 
revealed that combination treatment induces a systemic tumor-specific immunity with an indispensable role of both 
CD4+ and CD8+ T cells, and effector CD8+ T cells exhibited the antigen-specific cytokine secretion and cytotoxicity 
upon tumor antigen stimulation; additionally, combination treatment increased the IFN-γ-producing effector T cells 
and decreased the immunosuppressive cells in peritoneal cavity; accordingly, it enhanced the expression of Th1-asso-
ciated immune-stimulating genes while reducing the transcription of regulatory/suppressive immune genes, reshap-
ing tumor microenvironment from a immunosuppressive to a stimulatory state. Finally, in vivo Trabectedin treatment 
has been shown to induce IFN-γ-dependent PD-L1 expression within tumor, possibly constituting a mechanistic basis 
for its synergistic antitumor effect with α-PD-1 mAb therapy.
Conclusion: This study provides the evidence that α-PD-1 mAb can produce a synergistic antitumor efficacy when 
combined with Trabectedin, a clinically available anticancer agent, supporting a direct translation of this combination 
strategy in clinic for the treatment of ovarian cancer.
© 2015 Guo et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Ovarian carcinoma (OC) is the most lethal malignancy 
in women, with 22,280 new cases and 15,460 deaths esti-
mated in the United States for 2012 [1]. The high rate of 
lethality from OC is primarily due to the advanced stage 
of disease at diagnosis. Early stage cancers can be cured 
in up to 90% of patients with current therapies [2], but 
this rate drops substantially for advanced disease with 
approximately 30% of patients with advanced stage OC 
survive 5  years after initial diagnosis [3]. The standard 
treatment for ovarian cancer is surgical debulking fol-
lowed by platinum-taxane based chemotherapy [4]. 
Although most patients are responsive to chemotherapy 
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at first, the majority of them will eventually have a relapse 
and die of the disease. Therefore, novel strategies are 
urgently needed to improve the outcomes of ovarian 
cancer.
Lines of evidence suggest that OC should be amenable 
to the immunotherapy [5]. OC cells express many tumor-
associated antigens against which specific immune 
responses have been detected [6–10]; furthermore, 
endogenous anti-tumor immunity has been thought 
to impose a major impact on the outcomes of patients 
with OC as evidenced by the close correlation between 
patient survival and tumoral T cell infiltration in large 
annotated clinical samples [11]. Lastly, a uniquely advan-
tageous feature of OC is that their primary tumors and 
metastases are predominantly located in the peritoneal 
cavity where immunotherapeutic agents can be directly 
administered, thus bypassing systemic application and 
its associated adverse effects [12]. Despite the abundant 
evidence supporting OC immunotherapy, clinical success 
with immune-based therapies for OC has generally been 
modest [13].
Currently, checkpoint inhibitors have shown a great 
potential in the treatment of multiple types of cancer 
[14, 15], among which antibodies blocking programmed 
death 1 (PD-1) and its ligand PD-L1 produced an 
impressively therapeutic effect in multiple malignancies 
[16–21]. As for their application in OC, a clinical trial 
including a small cohort of OC patients demonstrated 
that treatment with α-PD-L1 antibody induced a durable 
antitumor response in a minority of patients (1 partial 
response and 3 stable disease in 17 patients lasting for 
at least 24  weeks) [16]; additionally, α-CTLA4 antibody 
ipilimumab has also been reported to increase antitumor 
effect of GM-CSF-modified autologous tumor cell vac-
cines [22, 23]. These preliminary clinical data suggest that 
immune checkpoint inhibitors are an excellent option 
for OC treatment though a giant space for improvement 
exists [24]. In this regard, our previous studies conducted 
in the ID8, a highly clinical relevant murine ovarian can-
cer, demonstrated that single checkpoint inhibitor such 
α-PD-1 or α-TIM3 antibody was ineffective in prevent-
ing peritoneal tumor growth while combined treatment 
with checkpoint inhibitors and immune-stimulating anti-
bodies produced a potently synergistic antitumor effect, 
leading to the regression of the established tumors [25, 
26]. The significantly improved effectiveness of combined 
treatment with checkpoint inhibitors is also validated in 
other preclinical studies [27–29] as well as a recent clini-
cal trial designed for treating melanoma [29]. Therefore, 
it is urgently needed to explore optimal combined strat-
egies to improve the antitumor efficacy of checkpoint 
inhibitors in OC treatment, which should be best directly 
translatable in clinic.
Trabectedin (ET-743) is a synthetic, marine-derived 
anticancer agent that binds to the minor groove of DNA, 
bending the helix to the major groove, resulting in per-
turbation of the cell cycle [30]. Trabectedin, in combina-
tion with pegylated liposomal doxorubicin hydrochloride 
(PLDH), has been approved by Food and Drug Admin-
istration (FDA) and Europe Medicine Agency (EMA) 
for the treatment of patients with relapsed platinum-
sensitive ovarian cancer [31, 32]. Recent studies demon-
strate the dual function of Trabectedin as it can not only 
directly kill tumor cells by interfering with cell cycle pro-
gression but also modulates tumor microenvironment 
via selective depletion of protumor monocytes, such as 
tumor-associated macrophages (TAM) and myeloid-
derived suppressor cells (MDSC) [33]. Based on the 
tumor-killing and immune-modulating activity of Tra-
bectedin, one would speculate that combined treatment 
of Trabectedin and checkpoint inhibitors should produce 
an additive and even synergistic antitumor effect in OC.
The present investigation was designed to explore the 
antitumor effect of combined Trabectedin and α-PD-1 
antibody in ID8 murine OC model. We further charac-
terized the cellular and molecular mechanisms driving 
this combined antitumor effect.
Methods
Mice
Female C57BL (6–8 week old) were purchased from 
the Animal Experimental Center of the China Medical 
University. Animal use was approved by our institution 
(China Medical University).
Cell lines
Murine ID8 ovarian cancer cells, TC-1 lung carcinoma 
cells and T cell lymphoma EL4 cells were all kept in our 
lab as previously described [25, 26]. Tumor cells were 
cultured in the complete DMEM medium supplemented 
with 10% FBS (Thermo Scientific, Rockford, IL), 100 U/
mL penicillin and 100  μg/mL streptomycin before cell 
suspensions were prepared and transplanted to mice. The 
EL4 cells and splenocytes were maintained in a complete 
medium of RPMI-1640 supplemented with 10% FBS, 
25  mM HEPES, 2  mM glutamine, 100  U/mL penicillin 
and 100 μg/mL streptomycin.
Reagents
Trabectedin was purchased from PharmaMar (Col-
menar Viejo, Madrid, Spain) and dissolved in DMSO 
to 1  mM (761.8  µg/mL) and kept at −20°C. Thera-
peutic α-PD-1 (Clone RMT3-23; Catalog#BE0115), 
α-CD4 (Clone GK1.5; Catalog#:BE0003-1), α-CD8 
(Clone 2.43; Catalog#:BE0061), α-NK1.1 (Clone 
PK136; Catalog#:BE0036), and control (Clone 2A3; 
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Catalog#:BE0089) mAb were purchased from BioXcell 
(West Lebanon, NH). Antibodies used for flow cytometry 
were purchased from Tianjing Sungene (Tianjing, China) 
and eBioscience (San Diego, CA).
Tumor challenge and treatment experiments
In the experiments with ID8 ovarian tumor, mice (6 
mice per group) were injected intraperitoneally (i.p.) 
with 1 ×  106 ID8 cells in 0.1  mL of PBS. Starting from 
10  days post-tumor injection, mice were treated with 
Trabectedin and/or α-PD-1 mAb as scheduled in Fig. 1a. 
Trabectedin was administered intravenously at a dose of 
200 µg/kg (body weight) once per week for 3 weeks while 
α-PD-1 mAb was peritoneally injected twice per week 
for 2 weeks. Control mice received the injection of PBS. 
The mice were weighted twice weekly and checked daily 
for the clinical sign of swollen bellies indicative of ascites 
information and for the evidence of toxicity such as res-
piratory distress, mobility, weight loss, diarrhea, hunched 
posture, and failure to eat while histopathology was con-
ducted on major organs (i.e., liver, kidney, intestines, 
lungs, and colon). Following institutional guidelines, 
mice were killed when they developed ascites and had a 
weight increase >30%. The survival of each mouse was 
recorded and overall survival was calculated.
For assessing the development of immune memory, 
pooled (2 independent experiment) 6 long-term sur-
viving mice (90  days after first tumor injection) from 
first combination treatment or age-matched naïve mice 
(which served as control) were challenged subcutane-
ously (s.c.) with 1 ×  106 ID8 cells or 1 ×  106 syngeneic 
but antigenically different TC1 cells. Three perpendicu-
lar diameters of s.c. tumors were measured every second 
day using a caliper and tumor volumes were calculated 
according to the formula: 1/2 × (length) × (width)2. Mice 
were sacrificed when they seemed moribund or their 
tumors reached 10 mm in diameter.
For depletion of immune cells, mice were injected i.p. 
with 500 μg of mAbs to CD8, CD4, CD4 plus CD8, or 
NK1.1, 1 day before and 2 days after tumor challenge, fol-
lowed by injection of 250 μg every 5 days throughout the 
experiment. The efficacy of cell depletion was verified by 
staining peripheral blood leukocytes for specific subsets 
after depletion (data not shown).
Fig. 1 Combined treatment with Trabectedin and α-PD-1 mAb mounted a durable tumor-specific immunity. a Schematic regimen for combination 
treatment in ID8 tumor model. b Mice (6 mice per group) were transplanted i.p. with 1 × 106 ID8 cells on day 0 and treated with either single or 
combined Trabectedin and α-PD-1 mAb as indicated in a, and overall survival of mice was recorded. c Median survival time of tumor-bearing mice 
was calculated. n indicates the number of tumor-bearing mice calculated. d Long-term surviving (90 days after first tumor challenge) mice from 
combination group (3 mice per group) were s.c. rechallenged with ID8 or unrelated TC1 tumor cells and their overall survival was recorded. e Naïve 
mice challenged with ID8 or TC1 tumor cells was used as control. f Mice (6 mice per group) receiving combination treatment were also injected 
with an α-CD4, α-CD8, α-CD4 plus α-CD8, α-NK1.1 or control mAb with 500 μg of each mAb per mouse 1 day before and 2 days after tumor chal-
lenge followed by injection of 200 μg every 5 days thereafter for the duration of the experiments and their overall survival were recorded. Data are 
representative of two (f) or three (b, c) independent experiments. *P < 0.05, ***P < 0.001.
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Evaluation of tumor‑associated immune cells (TIC)
Analysis of TIC composition was performed as previ-
ously described [25, 26]. Briefly, TIC were prepared from 
peritoneal lavage of treated mice 7 days after commence-
ment of treatment by using a mouse lymphocyte isola-
tion buffer (Cedarlane, Burlington, Ontario) following 
the manufacturer’s instruction. TIC were then washed 
with FACS staining buffer and incubated with mouse 
Fc receptor binding inhibitor (eBioscience) for 10  min 
before staining with mAbs (Tianjing Sungene) against 
mouse CD45 (clone 30-F11), CD3 (clone 145-2C11), 
CD4 (clone GK1.5), CD8 (clone 53-6.7), CD11b (clone 
M1/70) and Gr-1 (clone RB6-8C5) for 30 min. For intra-
cellular staining of FoxP3 (clone FJK-16s; eBioscience), 
cells were fixed, permeabilized and stained following the 
instruction of Cytofix/Cytoperm kit (BD Bioscience). For 
intracellular staining of IFN-γ (clone XMG1.2), cells were 
restimulated in vitro with 50 ng/mL PMA and 1 μg/mL 
ionomycin for 4 h prior to the analysis of IFN-γ secretion 
in CD4+ or CD8+ T cells. Flow cytometry was performed 
using FACSCalibur (BD Biosciences) and the lymphocyte 
population was selected by gating CD45-positive cells. 
The data were analyzed using Flow Jo software (Tree 
Star, Ashland, OR, USA). All flow cytometry experiments 
were performed at least two times.
Quantitative RT‑PCR
Quantitative RT-PCR was performed as previously 
described [25, 26]. Briefly, tumors were excised from 
treated mice 7 days after treatment commencement from 
which total RNA was extracted using RNeasy Mini Kits 
(Qiagen, Hilden, GA, USA) and reverse transcribed into 
cDNA using SuperScript III Reverse Transcriptase (Inv-
itrogen). Expression for genes of interest was analyzed 
in tumors harvested 7 days after tumor commence. The 
primers for all genes tested, including internal control 
GAPDH, were synthesized by Takara Inc., Dalian, China. 
Primer sequences were listed in Additional file  1: Table 
S1. Quantitative real-time PCR was performed via ABI 
PRISM 7500 Real-Time PCR Systerm (Applied Biosys-
tems) with 1 ×  SYBR Green Universal PCR Mastermix 
(Takara). Transcript levels were calculated according 
to the 2−ΔΔCt method, normalized to the expression of 
GAPDH, and expressed as fold change compared with 
control.
Evaluation of antigen‑specific CTL immune response
Isolated splenocytes from treated mice were cultured 
in the presence of 10  μg/mL H-2Db-restricted meso-
thelin-derived peptides (amino acid 406-414) or control 
HPV-E7-derived peptide (amino acid 49-57; all from 
GenScript, Nanjing, CA, USA) for 3 days. IFN-γ in the 
supernatants was determined by Mouse IFN-γ Quan-
tikine ELISA Kit (R&D systems, Minneapolis, MN, 
USA).
For CTL assays, effector cells were obtained by cocul-
turing 5 ×  106 splenocytes with 5 ×  105 UV-irradiated 
ID8 cells for 4 days. Peptide-pulsed EL4 target cells were 
generated by adding 10 μg/mL of peptide and incubating 
for 4 h. CTL activity was measured using the CytoTox96 
Non-Radioactive Cytotoxicity Assay kit (Promega, Madi-
son, WI, USA) following the manufacturer’s instructions. 
In brief, target cells were incubated with varying numbers 
of effector cells for about 4 h, and supernatants were then 
analyzed for lactate dehydrogenase release. The results 
are expressed as percent specific lysis, calculated as 
(Experimental release-Spontaneous release/Total release-
Spontaneous release) × 100. In some experiments, effec-
tor cells were incubated with anti-CD4 or CD8 antibody 
(10 μg/mL) for 2 h before CTL assay.
Evaluation of PD‑L1 within tumors
For PD-1 measurement by flow cytometry, B6 mice were 
inoculated i.p. with 1  ×  106 ID8 cells and treated with 
Trabectedin on day 10 and 17. On day 19, tumor masses 
harvested from mice were cut into small pieces, disaggre-
gated with collagenase (0.5 mg/mL), and filtered through 
strainers. Cells (106) were stained with APC conjugated 
anti-PD-L1 (clone 10F.9G2) or isotype control (clone 
eBR2a; rat IgG2a) mAb (all from Biolegend), and PD-L1 
expression was analyzed by flow cytometry as above. In 
addition, ID8 tumor cells (5  ×  105) cultured in 6-well 
plates were treated with peritoneal lavage fluid (20%, 
v/v) prepared from control or Trabectedin treated mice 
for 24 h and PD-L1 expression was then analyzed by flow 
cytometry. In some experiments, ID8 tumor cells treated 
with peritoneal lavage fluid from Trabectedin treated 
mice were cultured in the presence of isotype (clone 
RTK2071; rat IgG1) or anti-IFN-γ neutralizing antibody 
(clone AN-18; all from Biolegend).
For immunofluorescence staining, tumor masses har-
vested from treated mice were fixed with paraformalde-
hyde and blocked with 5% bovine serum albumin (BSA) 
for 45 min at room temperature. The samples were incu-
bated with anti-mouse PD-L1 (ab80276 from Abcam; 
1:100 in PBS  +  5% BSA), anti-mouse CD68 (ab53444 
from Abcam; 1:50 in PBS  +  5% BSA) or isotype con-
trol (ab18446 from Abcam) primary antibody at 4°C for 
16 h. An Alexa Fluor® 488-conjugated goat anti-rat IgG 
(H  +  L) polyclonal antibody (ab150157 from Abcam; 
1:200) was used as the secondary antibody. The samples 
were mounted in ProLong Gold anti-fade reagent (Life 
Technologies) and imaged on the Olympus FV1000 con-
focal microscope system.
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Statistics
Statistical analyses of all other data were performed by 
GraphPad Prism (Version 5.04, GraphPad Software, Inc). 
Results are presented as mean ± SEM obtained from at 
least two independent experiments. Differences between 
groups were tested by one-way or two-way ANOVA fol-
lowed by Tukey’s multiple comparisons test; Survival 
rates were analyzed using the Kaplan–Meier method and 
evaluated with the log-rank test with Bonferroni correc-
tion. Significant differences were accepted at p < 0.05.
Results
Combined Trabectedin and α‑PD‑1 mAb treatment 
synergistically induces a durable antitumor effect 
depending on both CD4+ and CD8+ T cells
As Trabectedin induces a profound growth inhibition 
and cell apoptosis in human ovarian cancer cell lines 
and our previous data showed that ID8 murine ovarian 
cancer cells do not express PD-1 and its ligand PD-L1 
on their surface [25], we first evaluated the direct effect 
of Trabectedin and/or α-PD-1 mAb on the survival of 
ID8 cells in  vitro. As expected, only Trabectedin inhib-
ited ID8 cell growth, whereas α-PD-1 mAb could neither 
inhibit ID8 cell growth directly nor enhance the inhibi-
tory effect of Trabectedin (Additional file 2: Figure S1).
We tested the antitumor efficacy, defined as prolonged 
overall survival, of single or combined Trabectedin and 
α-PD-1 mAb in C57BL/6 mice transplanted i.p. 10 days 
previously with 1 × 106 ID8 cells. Detailed treatment reg-
imen was shown in Fig. 1a. As described in our previous 
studies [25], single treatment with α-PD-1 mAb showed 
little antitumor effect, leading to ascites formation at the 
almost same time as control treated mice (about 30 days 
post-injection). Treatment with Trabectedin alone show 
a modest tumor-suppressing activity, resulting in a slight 
increase in overall survival (Fig.  1b); however, when 
tumor-bearing mice received the treatment of combined 
Trabectedin and α-PD-1 mAb, their overall survival were 
significantly prolonged with 50% (3 out of 6 mice) of mice 
surviving at the end of experiment (90 days after tumor 
injection), these long-term surviving mice were tumor 
free in peritoneal cavity when they were examined at 
postmortem; though remaining half of mice succumbed 
to tumor growth, their median survival time was mark-
edly longer than mice receiving control or single treat-
ment (Fig. 1c; median survival 33, 34, 37 and 89 days for 
control, α-PD-1, Trabectedin and Trabectedin/α-PD-1). 
Two repeats of the experiment gave similar results (data 
not shown). We did not observe any obvious toxicity 
such as weight or hair loss in mice receiving combination 
treatment.
Notably, those long-term survivors developed the sys-
temic tumor-specific memory immune response in that 
they were resistant to the rechallenge by s.c. injection of 
ID8 ovarian cancer cells but not s.c. injection of unre-
lated TC1 lung cancer cells (Fig. 1d) while naïve mice suc-
cumbed to them (Fig. 1e). Ninety days after rechallenge, 
100% (3 out of 3 mice) of mice remained tumor-free. 
Antibody-mediated cell depletion experiments demon-
strated that protection conferred by Trabectedin/α-PD-1 
treatment was dependent on the CD4+ and CD8+ T cells 
as the antitumor effect of this combination treatment was 
heavily compromised in the absence of CD4+ or CD8+ T 
cells (Fig. 1f ); NK cells play a minor role since removal of 
these cells slightly decreased the tumor protection.
Combined Trabectedin and α‑PD‑1 mAb treatment 
increases ratios of effector T cells to immunosuppressive 
cells in peritoneal lavage
To understand the synergistic mechanism of Trabect-
edin and PD-1 blockade in the ID8 tumor model, we 
evaluated the composition of tumor-associated immune 
cells (TIC) in peritoneal lavage of treated mice 7  days 
after treatment commence, focusing on antitumor 
effector CD4+FoxP3- and CD8+ T cells and immuno-
suppressive CD11b+GR-1+ MDSC and CD4+FoxP3+ 
regulatory T cells (Treg). Compared with control treat-
ment, α-PD-1 mAb treatment alone showed a modest 
effect on the composition of TIC with a slight decrease 
in immunosuppressive Treg which is consistent with 
our previous report (Fig. 2a; Ref [25]); though executing 
little effect on other immune subsets, single Trabect-
edin treatment significantly decreased the percent-
age of MDSC as previously described [33]; strikingly, 
combined Trabectedin and α-PD-1 mAb treatment 
significantly increased the percentage of effector 
CD4+FoxP3- T cells (mean value for Trabectedin/
α-PD-1 vs control, α-PD-1 and Trabectedin: 36.43 vs 
20.53, 20.97 and 24.43%; p  <  0.05) and CD8+ T cells 
(33.83 vs 10.03, 13.60 and 14.07%; p  <  0.01) while 
concomitantly diminishing that of immunosuppres-
sive Treg (2.03 vs 5.80, 4.00 and 5.23%; p  <  0.05) and 
MDSC (9.57 vs 30.77, 30.30, 18.80%; p < 0.05), resulting 
in a prominent elevation in the ratios of both effector 
CD4+FoxP3− and CD8+ T cells to immunosuppressive 
MDSC and Treg (Fig.  2b; CD4+FoxP3−/Treg: 18.37 vs 
3.56, 5.35 and 4.85, p < 0.001; CD8+/Treg: 17.44 vs 1.81, 
2.40 and 2.80, p  <  0.01; CD4+FoxP3−/MDSC: 4.16 vs 
0.68, 0.69 and 1.38, p < 0.01; CD8+/MDSC: 4.17 vs 0.32, 
0.32 and 0.76, p < 0.01). Regarding the absolute number 
of TIC, we observed a similar trend with a prominent 
increase in effector T cells and a decrease in immuno-
suppressive cells from combination treatment (Fig. 2c).
Further functional analysis showed that significantly 
elevated frequencies of IFN-γ-producing cells were 
seen in tumor-associated CD4+ and CD8+ T cells from 
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combination-treated mice (Fig.  3a). The representative 
dotplots were shown in Fig. 3b.
Together, these data indicate that combined treatment 
with Trabectedin and PD-1 blockade synergistically 
creates higher ratios of effector T cells to immunosup-
pressive cells in peritoneal cavity of treated mice, repre-
senting the shift of an immunosuppressive tumor milieu 
to an immunostimulatory state which is more permissive 
for immune mediated tumor destruction.
Combined Trabectedin and α‑PD‑1 mAb treatment shaped 
a local immunostimulatory microenvironment
To deepen insight into the experienced change of 
tumor immune microenvironment induced by com-
bination treatment, we performed expression profil-
ing of 20 immune-associated genes in tumors by using 
quantitative RT-PCR. As shown in Fig.  4a, combined 
Trabectedin/α-PD-1 mAb treatment induced a marked 
change of immune-associated genes marked by increased 
Th1 effector T cell recruitment (i.e., increased tran-
script expression for CXCR3 and its ligands CXCL9 and 
CXCL10) and functionality (i.e., increased transcripts 
for IFN-γ, IL-12p40 and T-bet). The tumor treated with 
Trabectedin/α-PD-1 mAb also exhibited the decreased 
protumor TAM/MDSC and Treg recruitment/accu-
mulation and (i.e., reduced transcript expression for 
CCL2, CXCL12, CD14, M-CSFR and FoxP3; Fig.  4b) 
and function (i.e., decreased expression of transcripts 
for IL-1β, IL-6, IL-10, TGF-β and VEGF as well as the 
MDSC-associated gene products arginase-1 and iNOS; 
Fig.  4c). Consistent with the above-mentioned analysis 
of TIC composition, treatment with Trabectedin alone 
decreased the expression of TAM/MDSC-associated 
marker (i.e., reduced transcripts for CCL2, CXCL12, 
CD14 and M-CSFR), function (i.e., reduced transcripts 
for arginase-1 and iNOS) and inflammatory cytokine (i.e., 
reduced transcripts for IL-1β and IL-6) genes while single 
α-PD-1 treatment attenuated the transcription of genes 
with Treg (i.e., reduced expression for IL-10, TGF-β and 
FoxP3). The depleting effect of Trabectedin on TAM 
was further confirmed by immunofluorescence staining 
where the number of CD68-postive TAM within tumors 
from mice treated with Trabectedin or Trabectedin/
α-PD-1 mAb significantly decreased compared with 
that from mice treated with control or singleα-PD-1 
mAb (Additional file 3: Figure S2). In sum, these results 
Fig. 2 Analysis of tumor-associated immune cells in peritoneal lavage from treated mice. Mice (6 mice per group) injected i.p. with 1 × 106 ID8 cells 
10 day earlier were treated as described in Fig. 1a. Seven days after treatment commencement, peritoneal lavage from treated mice was analyzed 
by flow cytometry for the percentages and numbers of various subsets of TIC. The percentages and absolute numbers of CD4+FoxP3−, CD8+, 
CD4+FoxP3+ Treg and CD11b+GR-1+ MDSC in peritoneal lavage are shown in a, c, respectively. The ratios of CD4+FoxP3− andvCD8+ T cells to Treg 
and MDSC in peritoneal lavage are shown in b. Data are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
Page 7 of 13Guo et al. J Transl Med  (2015) 13:247 
corroborate the above observation of the switch from an 
immunosuppressive to a predominantly antitumor Th1/
CTL response within tumors from combination treated 
mice.
Combined Trabectedin and α‑PD‑1 mAb treatment 
mounted an antigen‑specific CTL response
We next dissected the antigen-specific antitumor 
immune response by analyzing the splenocytes from 
treated mice stimulated with epitope peptide derived 
from mesothelin, a well-characterized tumor antigen 
expressed by ID8 tumor cells as previously described 
[25, 26]. As shown in Fig. 5a, splenocytes from combi-
nation-treated mice produced a significantly increased 
IFN-γ when stimulated with the H-2Db-restricted 
mesothelin-specific peptide as compared with that 
from mice of control or single treatment. We did not 
detected the increased secretion of IFN-γ in cultured 
splenocytes from all treated mice when they were 
stimulated with control HPV-E7 peptide, demonstrat-
ing that combination-treated mice mounted meso-
thelin-specific immune response. Further analysis of 
antigen-specific cytotoxicity showed that splenocytes 
from combination-treated mice exhibited a significant 
higher level of cytotoxic activity against EL4 cell pulsed 
with mesothelin but not with control HPV-E7 peptide 
(Fig.  5b, c). No cytotoxicity against either mesothelin 
or HPV-E7 peptide pulsed EL4 cells was detected from 
the splenocytes from mice receiving control or single 
treatment. Moreover, preincubation with CD8 anti-
body suppressed the cytolytic activity of splenocytes 
from combination-treated mice (Fig.  5d), suggesting 
that CD8+ T cells mediated the tumor antigen-specific 
killing effect.
Fig. 3 Functional analysis of IFN-γ production in peritoneal tumor-associated CD4+ and CD8+ T cells from treated mice. Mice (6 mice per group) 
inoculated i.p. with 1 × 106 ID8 cells 10 day earlier were treated as described in Fig. 1a. Seven days after treatment commencement, tumor-associ-
ated CD4+ and CD8+ T cells from peritoneal cavity of treated mice were assayed of IFN-γ production by intracellular cytokine staining. The frequen-
cies of IFN-γ-producing cells in tumor-associated CD4+ and CD8+ T cells are shown in a. The representative dotplots are shown in b with upper and 
bottom panels displaying IFN-γ staining in gated CD4+ and CD8+ T cells respectively. ISO designates the isotype staining. Data are representative of 
two independent experiments, **P < 0.01, ***P < 0.001.
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In vivo Trabectedin treatment induced PD‑L1 expression 
within ID8 tumors
As the presence of tumor antigen-specific preexisting 
T cells that are disabled by tumor PD-L1 expression is 
likely required for α-PD-1 mAb treatment to work [15], 
we speculate that Trabectedin treatment may induce 
tumoral PD-L1 expression by IFN-γ release from effect 
T cells, namely adaptive resistance mechanism recently 
described [34], thus providing the target for α-PD-1 
mAbs. To this end, we harvested the tumor masses from 
mice treated with control or Trabectedin and examined 
the PD-L1 expression by both flow cytometry and immu-
nofluorescence staining. Though control-treated tumors 
exhibited a negligible expression of PD-L1 on their 
surface, in  vivo Trabectedin treatment induced a pro-
nounced PD-L1 expression within tumors (Fig. 6a, b). In 
vitro direct treatment of ID8 with Trabectedin did not 
promoted the expression of PD-L1 (data not shown), 
indicating PD-L1 expression by in vivo Trabectedin treat-
ment is an indirect effect. As IFN-γ is a key inducer for 
PD-L1 expression and single Trabectedin treatment 
upregulated the expression of IFN-γ (Fig.  4a), we spec-
ulate that IFN-γ release from Trabectedin treatment 
induced the PL-L1 expression within tumors. To this end, 
we treated in  vitro cultured ID8 cells with lavage fluid 
from control or Trabectedin treated mice. As shown in 
Fig. 6c, lavage fluid from Trabectedin but control treated 
mice induced the PL-L1 expression, which can be largely 
prevented by the addition of IFN-γ-neutralizing but not 
control isotype antibody, supporting a key role of IFN-γ 
release in PD-L1 induction. The data indicate that in vivo 
Trabectedin treatment induced PD-L1 expression within 
tumors, which may constitute the basis for synergistic 
effect of combined Trabectedin/α-PD-1 mAb treatment.
Discussion
The immunotherapeutic modalities targeting single mol-
ecule or pathway remain insufficient to achieve dura-
ble clinical responses in patients with advanced OC 
[35], which is simply exemplified by the fact that single 
treatment with even “brilliant star” antibodies targeting 
immune checkpoint PD-1 did not produce an optimal 
antitumor response in OC patients [17], accordingly, 
studies from us and other groups found that single treat-
ment with α-PD-1 mAb showed little antitumor effect 
in mice bearing ID8 tumor [25–29]. These preclinical 
experiments and clinical practices as well as data from 
other tumors point to the importance of exploring the 
combination immunotherapy with rationale mechanisms 
[15, 36], in this regard, our previous studies demonstrate 
that concomitant checkpoint blockade and costimulatory 
molecule triggering, such as combined α-PD-1/α-OX40 
or α-TIM3/CD137 mAb, produced a highly synergis-
tic antitumor efficacy in ID8 tumor [25, 26]. However, 
except of α-PD-1 mAb, all other mAbs are in the early 
development [37], therefore, those promising strategies 
are currently impossible to be translated into clinic. To 
this end, we evaluated the synergistic antitumor efficacy 
of α-PD-1 mAb combined with Trabectedin, an antican-
cer agent with new mechanisms having been approved 
for the treatment of relapsed OC.
In this study, we demonstrate that combined 
Trabectedin/α-PD-1 mAb significantly inhibited the 
peritoneal tumor formation of ID8 ovarian cancer cells 
Fig. 4 Expression profiling of immune-associated genes in tumors 
from treated mice. a Mice (6 mice per group) inoculated i.p. with 
1 × 106 ID8 cells 10 day earlier were treated as described in Fig. 1a. 
Seven days after treatment commencement, tumors were excised 
and their RNA were extracted for the analysis of immune-associated 
gene expression by quantitative RT-PCR. a The expression of Th1-
related molecules CXCR3, CXCL9, CXCL10, T-bet, IL-12p40 and IFN-γ. 
b, c The expression of genes relating with TAM/MDSC and Treg 
recruitment/accumuation and function, including CCL2, CXCL12, 
CD14, M-CSFR, Arginase-1, iNOS, IL-1β, IL-6, IL-10, TGF-β, VEGF and 
FoxP3. *P < 0.05, **P < 0.01, ***P < 0.001.
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injected 10 days prior to treatment, resulting in the long-
lasting survival of 50% of mice, whereas either treatment 
alone was ineffective in tumor protection. More impor-
tantly, long-term survivors from combination-treated 
group are able to reject the rechallenge of the same 
tumors as first inoculation, but not unrelated tumors, 
suggesting the development of tumor-specific memory 
immunity in these mice. The findings support that com-
bined Trabectedin/α-PD-1 mAb treatment can mount a 
potently durable antitumor response, which may serve as 
a newly translatable immunotherapeutic option for the 
treatment of ovarian cancer.
We initially explored the cellular effector mechanisms 
by which combined treatment mediates a potent antitu-
mor effect of. Cell depletion experiments pinpoint to a 
pivotal role of both CD4+ and CD8+ effector T cells in 
tumor protection conferred by combination treatment 
since removal of each subset significantly attenuated 
the protective effect. Furthermore, analysis of TIC com-
position showed that combination treatment remark-
ably increased the accumulation of IFN-γ-producing 
CD4+ and CD8+ effector T cells, while concomitantly 
decreasing the immunosuppressive Treg and MDSC in 
peritoneal lavage, giving rise to the significantly increased 
ratios of both CD4+ and CD8+ effector T cells to the 
immunosuppressive cells, a long recognized determinant 
of productive antitumor immune response. The balance 
tipping toward antitumor effectors was also reflective in 
a prominently increased expression of Th1-associated 
immune genes and concomitantly decreased transcript 
for genes relating to the recruitment and functionality of 
Treg and MDSC in tumors. The data from the analysis of 
immune cell composition and immune gene expression 
in tumors support that combination treatment induces 
the shift of tumor immune microenvironment from the 
suppressive to the stimulatory state, which favorably con-
tributes to immune-mediated tumor destruction.
Additionally, we found that combination-treated mice 
developed an antigen-specific CD8+ T-cell immune 
response as evidenced by mesothelin epitope-specific 
IFN-γ production and cytotoxicity by splenic CD8+ T 
cells, also consistent with a pivotal role of CD8+ T cells 
in mediating tumor protection in these mice. As an 
endogenous non-mutated antigen, mesothelin should be 
Fig. 5 Mice treated with combined Trabectedin and α-PD-1 mAb developed a tumor antigen-specific CTL response. a Mice (6 mice per group) 
inoculated i.p. with 1 × 106 ID8 cells 10 day earlier were treated as described in Fig. 1a. Two weeks after treatment commencement, splenocytes 
from treated mice were cultured in the presence or absence of H-2Db-restricted mesothelin-derived peptides or control HPV-E7-derived peptide 
for 3 days and IFN-γ production in the supernatants were assayed by ELISA. b, c Splenocytes (5 × 106) from treated mice were incubated with 
5 × 105 UV-irradiated ID8 cells for 4 days prior to subjected to analysis of antigen-specific CTL activity by CytoTox 96 Non-radioactive cytotoxicity 
assay using EL4 cells pulsed with H-2Db-restricted mesothelin (b) or HPV-E7 peptide (c) as target cells. d The killing activity of restimulated spleno-
cytes from combination-treated mice was also evaluated in the presence of α-CD4, α-CD8 or control antibody. Data are expressed as M ± SEM of 
triplicate wells. *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 6 In vivo Trabectedin treatment induced PD-L1 expression within ID8 tumors. a Mice were inoculated i.p. with 1 × 106 ID8 cells and treated 
with control or Trabectedin on day 10 and 17. On day 19, harvested tumor cells from treated mice were stained with APC conjugated anti-PD-L1 
(black or red line for control or Trabectedin treatment) or isotype control antibody (filled gray line) for evaluating PD-L1 expression by flow cytometry. 
In vitro cultured ID8 tumor cells were included as a control (blue line). b Mice were treated as described in a, and harvested tumor tissues were 
analyzed for PD-L1 expression by immunofluorescence staining. Iso denotes isotype control staining. c In vitro cultured ID8 tumor cells were treated 
with peritoneal lavage fluid (20%, v/v) prepared from control (black line) or Trabectedin (red line) treated mice for 24 h and PD-L1 expression was 
then analyzed by flow cytometry (upper panels). In some experiments, ID8 tumor cells treated with peritoneal lavage fluid from Trabectedin treated 
mice were cultured in the presence of isotype or α-IFN-γ neutralizing antibody (bottom panels). Untreated ID8 cells were included as a control (blue 
line). Data are representative of two independent experiments.
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naturally tolerized against; the induction of mesothelin-
specific CD8+ T-cell immunity in this study demon-
strates that endogenous tolerance to mesothelin was 
overcome. The development of mesothelin-specific CD8+ 
T-cell immunity seems being a useful marker to predict 
a successful tumor protection as previous studies testing 
multiple immunotherapeutics in animals and humans 
also show a positive parallel between antitumor efficacy 
and mesothelin-specific CD8+ T-cell immunity [25, 26, 
29, 38, 39]. Thus, it may be an option to evaluating tumor 
antigen-specific immune responses against neoantigen 
or even endogenous non-mutated antigens to select can-
cer patients who would most benefit from checkpoint 
blockade therapies [40, 41]. Consistent with a critical role 
of CD4+ T cells in helping the formation of CD8+ CTL 
[42], depletion of CD4+ T cells also attenuated the pro-
tective effects induced by combination treatment. CD4+ 
CTL has also been described [43]; however, it remains 
to be determined whether CD4+ T cells in combination 
treated mice exhibit a cytolytic activity against tumors. In 
addition, we did not detect mesothelin-specific antibod-
ies in sera harvested 90 days after tumor challenge from 
combination treated mice by using flow cytometry-based 
approach previously described [26], but the presence of 
these antibodies cannot be completely excluded in view 
of comparatively low sensitivity of this approach and 
possibly suboptimal time point for sera collection. Seri-
ally collection of sera at different time points after treat-
ment and utilization of more sensitive approaches such 
as ELISA should be warrant in our future work.
The mechanisms for the synergy between α-PD-1 mAb 
and Trabectedin remain to be fully elucidated. Our data 
demonstrate that in vivo Trabectedin treatment induced 
the PD-L1 expression within tumors, which may be par-
tially responsible for the synergistic antitumor effect of 
combined Trabectedin and α-PD-1 mAb as tumor PD-L1 
expression disabling the antitumor function of preexist-
ing tumor antigen-specific T cells has been thought to be 
prerequisite for α-PD-1 mAb therapy to work [15]. Pre-
vious studies have demonstrated that chemotherapeutic 
drugs can also potentiate or induce PD-L1 expression 
on tumor cells by either indirect (IFN-γ-dependent) or 
direct (ERK signal-mediated) manner [44, 45]. Together 
with our results, these studies provide evidence that sev-
eral chemotherapeutic drugs have the capacity to induce 
PD-L1 expression, which may itself mediate the chemo-
therapy resistance on the one hand [46], but also provide 
the rationale for combined cancer treatment of chemo-
therapeutic drugs and anti-PD-1/PD-L1 mAbs on the 
other hand. In fact, anti-PD-1 mAb has been reported 
to show acceptable toxicity profile and encouraging anti-
tumor activity in combination with chemotherapy in 
patients with advanced non-small cell lung cancer [47]. 
Thus, future studies are warranted to evaluate the effect 
of other chemotherapeutic drugs on tumoral PD-L1 
expression to find out the optimal matching drugs for 
combined cancer treatment with anti-PD-1/PD-L1 
mAbs.
Conclusion
We reported that α-PD-1 mAb can produce a potently 
durable antitumor immune response when combined 
with Trabectedin, a clinically available antitumor agent. 
The findings provide proof-of-concept evidence for com-
bined Trabectedin/α-PD-1 mAb treatment of advanced 
OC. Certainly, more detailed regimen studies are needed 
to obtain an optimal therapeutic index (maximal anti-
tumor efficacy and minimum side effects) using improved 
mouse models before translating it to clinic.
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